Gupta Jitendra, Kareem Al-Hetty Hussein Riyadh Abdul, Aswood Murtadha Sh, Turki Jalil Abduladheem, Azeez Maha Dhurgham, Aminov Zafar, Alsaikhan Fahad, Ramírez-Coronel Andrés Alexis, Ramaiah Pushpamala, Farhood Bagher
Institute of Pharmaceutical Research, GLA University, Mathura, India.
Department of Nursing, Al-Maarif University College, Ramadi, Anbar, Iraq.
Front Oncol. 2023 May 2;13:1173827. doi: 10.3389/fonc.2023.1173827. eCollection 2023.
Cancer is caused by defects in coding and non-coding RNAs. In addition, duplicated biological pathways diminish the efficacy of mono target cancer drugs. MicroRNAs (miRNAs) are short, endogenous, non-coding RNAs that regulate many target genes and play a crucial role in physiological processes such as cell division, differentiation, cell cycle, proliferation, and apoptosis, which are frequently disrupted in diseases such as cancer. MiR-766, one of the most adaptable and highly conserved microRNAs, is notably overexpressed in several diseases, including malignant tumors. Variations in miR-766 expression are linked to various pathological and physiological processes. Additionally, miR-766 promotes therapeutic resistance pathways in various types of tumors. Here, we present and discuss evidence implicating miR-766 in the development of cancer and treatment resistance. In addition, we discuss the potential applications of miR-766 as a therapeutic cancer target, diagnostic biomarker, and prognostic indicator. This may shed light on the development of novel therapeutic strategies for cancer therapy.
癌症是由编码和非编码RNA的缺陷引起的。此外，重复的生物途径会降低单靶点抗癌药物的疗效。微小RNA（miRNA）是短的内源性非编码RNA，可调节许多靶基因，并在细胞分裂、分化、细胞周期、增殖和凋亡等生理过程中发挥关键作用，而这些生理过程在癌症等疾病中经常被破坏。MiR-766是适应性最强、保守性最高的微小RNA之一，在包括恶性肿瘤在内的几种疾病中显著过表达。MiR-766表达的变化与各种病理和生理过程有关。此外，MiR-766在各种类型的肿瘤中促进治疗抵抗途径。在这里，我们展示并讨论了表明MiR-766与癌症发展和治疗抵抗相关的证据。此外，我们还讨论了MiR-766作为癌症治疗靶点、诊断生物标志物和预后指标的潜在应用。这可能为癌症治疗新策略的开发提供启示。
